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Abstract Plasmalogen-specific, calcium-independent phospho-
lipase A2 (iPLA2) is activated during myocardial ischemia.
Accordingly, we have assessed the activation of myocardial
protein kinases by the iPLA2 product, lysoplasmenylcholine.
Lysoplasmenylcholine-activated protein kinase activity from
heart cytosol fractionated on a DE-52 column was identified as
cAMP-dependent protein kinase (PKA) based on the following:
(1) protein kinase activity stimulated by cAMP and lysoplas-
menylcholine co-eluted on sequential chromatographic steps; (2)
lysoplasmenylcholine-activated protein kinase activity was in-
hibited by the PKA inhibitor, PKI; and (3) the unprimed PKA
form generated from the primed form of PKA was activated by
cAMP and lysoplasmenylcholine. These results demonstrate a
novel mechanism for PKA activation by lysoplasmenylcholine.
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1. Introduction
Plasmalogens are the predominant phospholipid constitu-
ents of myocardial sarcolemma [1,2]. Although plasmalogens
are likely important regulators of trans-sarcolemmal proteins
such as the sodium-calcium exchanger [3], the physiological
role of plasmalogens is only partially understood. The pres-
ence of plasmalogens in plasma membranes suggests that their
hydrolysis by phospholipases could result in the generation of
plasmalogenic lipid second messengers. In fact, plasmalogen-
speci¢c iPLA2 is rapidly activated in myocardial membranes
over 4-fold within 2 min of global ischemia [4]. Furthermore,
plasmalogen-speci¢c iPLA2 activation has been demonstrated
in cardiac myocytes stimulated with IL-1 and thrombin [5,6].
Additionally, plasmalogens can be hydrolyzed by choline glyc-
erophospholipid-speci¢c PLC [7] and the product of this en-
zyme activity (i.e. 1-O-alk-1P-enyl-2-acyl-sn-glycerol) accumu-
lates during myocardial ischemia [7,8]. Very little, however, is
known about the e¡ects of the metabolic products from the
breakdown of plasmalogens in myocardial cells.
As an initial step in identifying the biological activities of
the iPLA2 hydrolysis product of plasmenylcholine, we have
assessed the activation of myocardial protein kinases by lyso-
plasmenylcholine. The present study demonstrates that myo-
cardial cAMP-dependent protein kinase (PKA) is activated by
lysoplasmenylcholine as well as other choline-containing lyso-
phospholipids. This mechanism may represent a key signal
transduction mechanism for the phosphorylation of mem-
brane-bound proteins by PKA.
2. Materials and methods
2.1. Reagents and purity of lipid species
Plasmenylcholine, plasmenylethanolamine, lysoplasmenylcholine,
and lysoplasmenylethanolamine were prepared as previously described
[9]. Phosphatidylcholine and lysophosphatidylcholine were purchased
from Avanti Polar Lipids (Alabaster, AL). Phosphocholine, and chol-
ine were the purest available and were purchased from Sigma Chem-
ical (St. Louis, MO). Organic solvents were purchased from Fisher
Chemical. DEAE sepharose fast £ow resin and Mono Q columns were
purchased from Pharmacia-LKB (Piscataway, NJ). Preparations of
PKA catalytic and regulatory subunits were obtained from Promega
(Madison, WI). All other reagents were of the highest grade available
and were purchased from Sigma Chemical (St. Louis, MO).
2.2. Preparation of rabbit heart cytosol
New Zealand White rabbits (6 1 kg) were cervically dislocated and
their hearts excised immediately and placed into normal saline solu-
tion (0.9% NaCl). Hearts were trimmed of fat, connective tissue, and
atrial tissues, and the ventricular tissue was minced at 4‡C in 5 vol-
umes (w/v) of homogenization bu¡er (300 mM sucrose, 1.2 mM di-
thiothreitol, 1.2 mM EDTA, 24 mM Tris, pH 7.5) and then homog-
enized in a Potter-Elvehjem tube with a rotating Te£on pestle. The
suspension was then subjected to treatment with a Polytron for 2 min
at a setting of 4. The homogenate was centrifuged at 10 000Ugmax for
10 min at 4‡C. The resulting supernatant was decanted and then
subjected to ultracentrifugation at 100 000Ugmax for 1 h at 4‡C. Cy-
tosol (supernatant) was decanted and dialyzed twice against 2 l of
bu¡er A (10 mM L-mercaptoethanol, 0.5 mM EDTA, 0.5 mM
EGTA, 20 mM Tris, pH 7.8) at 4‡C. Dialyzed cytosol was then
¢ltered through glass wool prior to anion exchange chromatography.
2.3. Chromatographic puri¢cation of lysoplasmenylcholine-activated
protein kinase
Anion exchange chromatography was performed using either a 10
ml DEAE sepharose fast £ow or DE-52 column. The column was ¢rst
equilibrated with 50 ml of bu¡er A and then loaded with 25 ml of
¢ltered cytosol. Following a 50 ml wash of the column with bu¡er A,
myocardial protein kinases were eluted from the DEAE sepharose fast
£ow column with a linear gradient from 0 to 300 mM NaCl in bu¡er
A at a £ow rate of 1 ml/min. During gradient elution, 5 ml fractions
were collected. For DE-52 anion exchange chromatography, myocar-
dial protein kinases were eluted by a 100 ml gradient from bu¡er A to
bu¡er A containing 300 mM NaCl. Fractions were assayed for kinase
activity with cAMP or lysoplasmenylcholine using the Kemptide
phosphorylation assay or the myocardial protein phosphorylation as-
say (vide infra).
Primed and unprimed PKA were separated using FPLC on a Mono
Q column using a Beckman Bio Sys 500. The column was equilibrated
with 25 ml bu¡er A and then loaded with 2 ml of pooled fractions
from DEAE sepharose fast £ow chromatography which contained
lysoplasmenylcholine-activated protein kinase activity. The primed
and unprimed forms of PKA were eluted from the Mono Q column
with a 0 to 500 mM NaCl gradient in bu¡er A over 75 min at a £ow
rate of 1 ml/min. Fractions were collected at one minute intervals and
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assayed for kinase activation with cAMP or lysoplasmenylcholine us-
ing the Kemptide phosphorylation assay. For removal of cAMP from
PKA, a 2 ml aliquot of pooled DEAE fractions containing lysoplas-
menylcholine-activated protein kinase was treated with 0.125 U of
phosphodiesterase (Boehringer Mannheim) at 30‡C for 45 min and
then immediately injected onto the Mono Q column for FPLC anal-
ysis.
2.4. Hydroxyapatite column chromatography of
lysoplasmenylcholine-activated protein kinase
Anion exchange chromatography-puri¢ed, lysoplasmenylcholine-ac-
tivated protein kinase was subsequently subjected to hydroxyapatite
chromatography. In brief, DE-52-puri¢ed kinase was loaded onto a
Koken high-performance hydroxyapatite column (0.6U13 cm) that
was equilibrated with bu¡er B comprised of 0.5 mM EGTA, 0.5
mM EDTA, 10 mM L-mercaptoethanol and 20 mM potassium phos-
phate (pH 7.4). Protein kinase activity was eluted from the column by
a 60 ml gradient from 20 mM to 280 mM potassium phosphate at a
£ow rate of 1 ml/min. One ml fractions were collected and UV ab-
sorbance was monitored at 280 nm. Protein kinase activity was de-
tected utilizing the Kemptide phosphorylation assay.
2.5. Puri¢cation of cAMP-dependent protein kinase
Protein kinase A holoenzyme was puri¢ed from rabbit heart cytosol
following a modi¢cation of the method described by Cobb et al. [8].
Brie£y, rabbit heart cytosol was subjected to fractionation by DEAE
sepharose fast £ow anion exchange column chromatography (vide
supra). Fractions exhibiting kinase activity stimulated by both
cAMP and lysoplasmenylcholine were pooled and 160 g/l ammonium
sulfate was added. After incubation for 1 h, the pooled fractions were
centrifuged at 17 000Ugmax for 30 min. An additional 270 g/l of am-
monium sulfate was added to the supernatant and gently stirred for
1 h. The precipitated proteins were then pelleted by centrifugation at
17 000Ugmax for 30 min and subsequently resuspended in bu¡er A.
The conductivity of the enzyme solution was adjusted with additional
bu¡er A until the conductivity equalled that of 1.2 M ammonium
sulfate in bu¡er A. The enzyme was clari¢ed by centrifugation at
17 000Ugmax for 30 min and the supernatant loaded onto a 1 ml
phenyl sepharose column. The column was washed by the application
of 1 ml of 1 M ammonium sulfate in bu¡er A followed by 2 ml of 0.2
M ammonium sulfate in bu¡er A and the enzyme was eluted with
5 ml of 1 mM potassium phosphate, 0.1 mM EDTA, and 2 mM L-
mercaptoethanol (pH 6.8). The phenyl sepharose fractions (1 ml)
were assayed for kinase activity using the Kemptide phosphorylation
assay.
2.6. Kemptide phosphorylation assay
Lysoplasmenylcholine-activated myocardial protein kinase activity
from column fractions was determined by modi¢cations of the meth-
od described by Roskoski [10]. Brie£y, 25 Wl of the fraction containing
lysoplasmenylcholine-activated protein kinase was incubated in assay
bu¡er (50 mM MOPS, pH 7.0, 10 mM MgCl2, 0.25 mg/ml BSA, 100
WM [32P]ATP (77 cpm/pmol), 100 WM Kemptide) and either selected
concentrations of lipid activators, 10 WM cAMP, or no activators in a
¢nal volume of 200 Wl at 30‡C for 15 min. Reactions were terminated
by spotting 80 Wl of each assay sample onto phosphocellulose ¢lters
(2.4 cm, Whatman) and washed 3 times in 75 mM phosphoric acid for
2 min each. Protein kinase activity was quantitated by counting the
phosphocellulose ¢lters by Cerenkov counting. For experiments in-
volving the inhibition of PKA, PKI was added at concentrations of
either 0.5, 5 or 50 WM to the assay bu¡er before the addition of the
stimulant.
2.7. Assay of myocardial protein phosphorylation stimulated by
lysoplasmenylcholine
To identify myocardial proteins that are phosphorylated by lyso-
plasmenylcholine-activated protein kinase in column chromatography
fractions, 10 Wl of individual or pooled DE-52 fractions were incu-
bated in reaction bu¡er (20 mM Tris, pH 7.4, 10 mM MgCl2, and 10
WM [32P]ATP (1000 cpm/pmol) in a volume of 100 Wl at 30‡C for
5 min. Endogenous kinase activity was stimulated by the addition
of 50 WM lysoplasmenylcholine. Phosphorylation reactions were
stopped by the addition of 100 Wl of SDS-PAGE sample bu¡er fol-
lowed by boiling. Samples were separated on 10% SDS-PAGE gels
and the phosphoproteins visualized by autoradiography following 24 h
of exposure.
3. Results
3.1. Identi¢cation of a myocardial protein kinase that is
activated by lysoplasmenylcholine
As an initial step in the delineation of the biological targets
of lysoplasmenylcholine produced by iPLA2, the activation of
myocardial protein kinases by lysoplasmenylcholine was de-
termined in column fractions from DE-52 anion exchange
chromatography of rabbit heart cytosol. Fractions were as-
sayed for kinase activity in the presence and absence of 50
WM lysoplasmenylcholine utilizing proteins present in each
fraction for both kinase activity and protein kinase substrates
with activity determined by autoradiography of 32P-labeled
proteins as described in Section 2. Protein kinase activity
that was activated by lysoplasmenylcholine eluted in fractions
9 through 13 corresponding with a sodium chloride concen-
tration of V150 mM (Fig. 1A). Fig. 1B demonstrates the
dependence of kinase activity in fraction 9 on the presence
of 50 WM lysoplasmenylcholine. Subsequently, it was deter-
mined that this kinase activity could phosphorylate Kemptide
and further assays employed this phosphorylation assay sys-
tem. Fig. 2A depicts a typical plot of the myocardial protein
kinase activity from DEAE sepharose fast £ow fractions of
rabbit heart cytosol utilizing the Kemptide phosphorylation
assay. Under these conditions, kinase activity stimulated by
lysoplasmenylcholine is identi¢ed in a peak centered around
fraction 48 at a NaCl concentration of V150 mM. Lysoplas-
menylcholine did not activate any other myocardial protein
kinases including protein kinase C which elutes prior to lyso-
plasmenylcholine-activated protein kinase. When the same
fractions were stimulated with cAMP, kinase activity co-
eluted with that activated by lysoplasmenylcholine (Fig. 2A).
The anion exchange-puri¢ed lysoplasmenylcholine-activated
protein kinase was further puri¢ed by hydroxyapatite chro-
matography (Fig. 2B) and lysoplasmenylcholine-activated
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Fig. 1. Protein phosphorylation stimulated by lysoplasmenylcholine
in DE-52 fractionated rabbit heart cytosol. Cytosol was prepared
from rabbit myocardium and was fractionated by DE-52 column
chromatography as described in Section 2. To expedite the identi¢-
cation of protein kinases activated by lysoplasmenylcholine, aliquots
of fractions were pooled and assayed for kinase activity (panel A;
lane 1, fractions 3 and 4; lane 2, fractions 5 and 6; lane 3, fractions
7 and 8; lane 4, fractions 9 and 10; lane 5, fractions 11 and 12;
and lane 6, fractions 13 and 14). Protein kinase activity was identi-
¢ed in each pooled fraction by the addition of [32P]ATP, 50 WM ly-
soplasmenylcholine, and other cofactors with analysis of phospho-
proteins by autoradiography of SDS-PAGE gels as described in
Section 2. Kinase activity stimulated by lysoplasmenylcholine in
fraction 9 was assessed in the presence or absence (+ or 3) of lyso-
plasmenylcholine (50 WM) (panel B).
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protein kinase activity again co-eluted with cAMP-stimulated
kinase activity. The results from these experiments clearly
demonstrate the presence of a myocardial kinase (lysoplas-
menylcholine-activated protein kinase) that can be activated
by one of the products of iPLA2 in rabbit myocardium (i.e.
lysoplasmenylcholine).
3.2. Identi¢cation of lysoplasmenylcholine-activated protein
kinase as PKA
The observations that lysoplasmenylcholine-activated pro-
tein kinase activity co-eluted with PKA activity in fractions
obtained from the anion exchange chromatography and hy-
droxyapatite chromatography suggested that the protein kin-
ase stimulated by lysoplasmenylcholine was PKA. As an ini-
tial approach to testing this hypothesis, the cAMP-dependent
protein kinase inhibitor was utilized in Kemptide phospho-
rylation assays using lysoplasmenylcholine or cAMP as stimu-
lants. The addition of PKI to the Kemptide assays completely
inhibited the myocardial protein kinase activity stimulated by
both cAMP and lysoplasmenylcholine (Fig. 3). These results
were predicted since PKI inhibits kinase activity by binding to
the substrate binding site of the protein kinase and since both
PKA and lysoplasmenylcholine-activated protein kinase phos-
phorylate the synthetic Kemptide substrate used in the assay.
It should also be noted that Kemptide is not a speci¢c sub-
strate of PKA, other protein kinases such as S6 kinase can
phosphorylate Kemptide [11]. Accordingly, alternative strat-
egies were employed to identify lysoplasmenylcholine-acti-
vated protein kinase as PKA. The PKA holoenzyme was par-
tially puri¢ed utilizing multiple chromatographic and
fractionation steps by the procedure described by Cobb and
co-workers [12]. Rabbit heart cytosol was fractionated by
anion exchange chromatography and the fractions with lyso-
plasmenylcholine-stimulated protein kinase activity were
pooled, the enzyme precipitated by the addition of ammonium
sulfate, and subjected to phenyl sepharose chromatography.
After each step in the puri¢cation process, the lysoplasmenyl-
choline-stimulated kinase activity was observed to coincide
with cAMP-stimulated kinase activity (data not shown).
Further support for the conclusion that lysoplasmenylcho-
line-activated protein kinase is PKA was accrued from experi-
ments designed to interconvert the primed and unprimed
forms of PKA which are readily puri¢ed by anion exchange
chromatography [12]. The unprimed form of PKA is charac-
terized as being cAMP free and the primed form of PKA is
characterized as having half of the cAMP binding sites con-
taining bound cAMP [12]. An interesting feature of this sys-
tem is that upon removal of cAMP by phosphodiesterase
from the primed PKA fractions, rechromatography yields
the unprimed form of PKA. Therefore, PKA from anion ex-
change chromatography of rabbit heart cytosol was separated
by FPLC on a Mono Q column. PKA activity was measured
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Fig. 3. Inhibition of lysoplasmenylcholine-activated protein kinase
activity by the PKA inhibitory peptide. Mono Q-puri¢ed lysoplas-
menycholine-activated protein kinase from DE-52 fractionated rab-
bit heart cytosol was assayed for kinase activity utilizing the Kemp-
tide phosphorylation assays as described in Section 2. Assays were
performed in the presence of either 50 WM lysoplasmenylcholine or
10 WM cAMP as well as in the presence or absence of either 0.5,
5 or 50 WM PKI. Each data bar represents the mean of three inde-
pendent assays.
Fig. 2. Chromatographic separation of lysoplasmenylcholine-activated protein kinase. Proteins from rabbit heart cytosol were fractionated by
DEAE sepharose fast £ow chromatography as described in Section 2. The even numbered fractions from 22^60 were assayed independently for
myocardial protein kinase activity stimulated by no stimulant (b), 10 WM cAMP (F), or 100 WM lysoplasmenylcholine (a) in the Kemptide
phosphorylation assay (Section 2) (panel A). Anion exchange chromatography-puri¢ed lysoplasmenylcholine-activated protein kinase was subse-
quently subjected to FPLC hydroxyapatite chromatography as described in Section 2. Protein kinase activity was detected in the fractions using
the Kemptide phosphorylation assay as described in Section 2 using cAMP (F) or lysoplasmenycholine (a) as the stimulants (panel B).
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using cAMP and lysoplasmenylcholine as activators and the
results indicated that all of the PKA activity is present in the
primed form as peak 2 which also exhibited activity stimu-
lated by lysoplasmenylcholine (Fig. 4A). When the primed
fractions of PKA were treated with phosphodiesterase and
rechromatographed, the formation of the unprimed peak 1
of PKA activity was observed along with a residual peak of
PKA in the primed state resulting from incomplete removal of
cAMP (Fig. 4B). Additionally, this unprimed peak of PKA
now is activated by lysoplasmenylcholine (Fig. 4B). To con-
¢rm that the primed and unprimed peaks had been success-
fully separated, primed PKA was treated with phosphodies-
terase and then loaded onto the Mono Q column in equal
volumes with untreated primed PKA. The results obtained
indicate that the added untreated primed PKA increases
peak 2 with the unprimed peak still evident (Fig. 4C). Both
the primed and unprimed forms of PKA are e¡ectively sepa-
rated and are both activated by lysoplasmenylcholine. Thus it
is concluded that lysoplasmenylcholine stimulates PKA in
both the primed and unprimed forms and that cAMP is not
required for the stimulation of the unprimed form.
To further demonstrate the activation of PKA by lysoplas-
menylcholine, commercially available, preparations of both
the catalytic and regulatory subunits of PKA puri¢ed from
bovine heart were assayed for protein kinase activity in the
presence and absence of lysoplasmenylcholine using the
Kemptide phosphorylation assay. Fig. 5 demonstrates that
the activity of the catalytic subunit alone is constitutive and
exhibits maximal protein kinase activity independent of the
activator present which is due to the absence of the regulatory
subunit. Protein kinase assays performed on the regulatory
subunit alone exhibited no protein kinase activity in the pres-
ence of the activators due to the fact that no catalytic subunit
was present (Fig. 5). The addition of the regulatory subunit to
the catalytic subunits prior to measurement of protein kinase
activity prevented catalytic activity in the absence of cAMP or
lysoplasmenylcholine. The addition of cAMP as an activator
releases the inhibitory e¡ects of the regulatory subunit and
activates the protein kinase. Similar to cAMP, the addition
of lysoplasmenylcholine to the combined catalytic and regu-
latory subunits releases the inhibitory e¡ects of the regulatory
subunits and activates protein kinase activity. Thus it is con-
cluded that lysoplasmenylcholine stimulates commercial prep-
arations of PKA in a cAMP-independent manner and further
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Fig. 5. Reversal of regulatory subunit inhibition of catalytic subunit
activity by cAMP or lysoplasmenylcholine. PKA catalytic (1 unit)
(C) and regulatory (1.5 units) (R) subunits were assayed for protein
kinase activity using the Kemptide phosphorylation assay as de-
scribed in Section 2. For conditions utilizing both the catalytic and
regulatory subunits (C+R), 0.5 units of catalytic and 0.75 units of
regulatory subunits were combined and incubated on ice for 5 min
prior to Kemptide phosphorylation assays. Assays were performed
in the presence of no activator, 10 WM cAMP, or 50 WM lysoplas-
menylcholine as indicated. Each value represents the mean+standard
deviation of three independent assays.
Fig. 4. Separation of unprimed and primed PKA conformations by
FPLC and activation by lysoplasmenylcholine. Partially puri¢ed
rabbit myocardial PKA from anion exchange chromatography was
subjected to FPLC through a Mono Q column (Section 2) and then
assayed for protein kinase activity using the Kemptide phosphoryla-
tion assay and 10 WM cAMP (F) or 100 WM lysoplasmenylcholine
(a) as stimulants as described in Section 2 (panel A). Mono Q-puri-
¢ed PKA in the primed conformation was pooled and treated with
0.125 U of phosphodiesterase and rechromatographed by FPLC
through a Mono Q column (Section 2) and then assayed for protein
kinase activity as described in panel A (panel B). Mono Q-puri¢ed
PKA in the primed conformation and primed PKA treated with
phosphodiesterase were simultaneously subjected to FPLC through
a Mono Q column and then assayed for protein kinase activity as
described in panel A (panel C).
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supports our observation of myocardial PKA activation by
lysoplasmenylcholine.
3.3. Demonstration of speci¢city and concentration dependence
of lipidic activators of PKA
To explore the speci¢city of the activation of PKA by ly-
soplasmenylcholine, structurally similar lipids were tested at
selected concentrations for activation of PKA. PKA is specif-
ically activated by choline lysophospholipids (Fig. 6A). Other
lysophospholipid classes such as lysoplasmenylethanolamine
and lysophosphatidylserine did not stimulate kinase activity
(Fig. 6A). Additionally, activation by choline-containing lyso-
phospholipids possesses a subclass speci¢city with an order
for activation of lysoplasmenylcholines lysophosphatidylcho-
lines lyso-PAF (lyso-platelet activating factor, 1-O-alkyl-
glycero-3-phosphocholine) with PAF not activating PKA
(Fig. 6B). The speci¢city of lysoplasmenylcholine-activated
protein kinase activation by choline-containing lysophospho-
lipids is underscored by the demonstration that substitution of
the hydroxyl group at the sn-2 position with an acetate results
in a lipid molecule (PAF) which does not activate PKA (Fig.
6B).
To pursue the choline-containing lysophospholipid speci¢c-
ity for PKA activation further, we examined the ability of
phosphatidylcholine, phosphocholine, and choline to activate
the PKA. At concentrations of 1, 10, and 100 mM, none of
the choline derivatives stimulated PKA (data not shown). This
suggests that choline or phosphocholine alone is not su⁄cient
to activate the myocardial protein kinase. These observations
underscore the speci¢city of PKA for lysophospholipids con-
taining choline polar head groups.
4. Discussion
The results described herein provide evidence that lysoplas-
menylcholine activates PKA in vitro. A peak of lysoplasmen-
ylcholine-activated protein kinase activity was initially identi-
¢ed in rabbit myocardial cytosol fractionated by DE-52
anion exchange chromatography. The identity of the lysoplas-
menylcholine-activated protein kinase activity was determined
to be PKA based on four salient observations: First, protein
kinase activity stimulated by both cAMP and lysoplasmenyl-
choline co-eluted on multiple chromatographic steps including
anion exchange, high-performance hydroxyapatite, phenyl se-
pharose, and Mono Q column chromatographies. Second,
protein kinase activity stimulated by lysoplasmenylcholine
was inhibited through the use of PKI. Third, lysoplasmenyl-
choline-activated protein kinase was able to phosphorylate the
synthetic PKA peptide substrate, Kemptide. Finally, cAMP
and lysoplasmenylcholine stimulated protein kinase activity
in Mono Q FPLC-resolved primed and unprimed forms of
PKA. Additionally, the activation of PKA by lysophospholip-
ids was speci¢c for lysophospholipids containing choline polar
head groups.
The variety of phospholipids which comprise biological
membranes provides a depot of diverse precursors for the
generation of numerous possible second messengers (cf.
[13]). Many signal transduction pathways are initiated by
the activation of phospholipases located at biological mem-
branes which hydrolyze phospholipids to produce lipid second
messengers. Similarly, it is possible that the production of
lysoplasmenylcholine by iPLA2 at the level of the plasma
membrane may represent an important process in signal trans-
duction. Although lysoplasmenylcholine content in subcellular
membrane domains of myocardium remains to be determined,
it is possible that lysoplasmenylcholine production in speci¢c
membrane domains may represent a biochemical mechanism
designed to target PKA activation and subsequent protein
phosphorylation to membranes where phospholipolysis is oc-
curring. It is possible that increased levels of cAMP and ly-
soplasmenylcholine in the cell may act synergistically to both
activate and target PKA to speci¢c subcellular membrane
compartments. Regulation of this mechanism would likely
be controlled by the activation of iPLA2 and lysophospholipid
acyltransferase activities.
The relationship between phospholipases and the activation
of kinases by phospholipid intermediates is well appreciated.
For example, the family of protein kinase C isozymes repre-
sents the major downstream targets for lipid second messen-
gers produced by phospholipases (cf. [13]). Protein kinase C
isozymes are di¡erentially activated by the products of phos-
pholipase A2 (free fatty acids and lysophospholipids), phos-
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Fig. 6. Speci¢city and concentration dependence of lipidic activators of lysoplasmenylcholine-activated protein kinase. Mono Q-puri¢ed PKA
from DE-52 fractionated rabbit heart cytosol was assayed for kinase activity utilizing the Kemptide phosphorylation assay as described in Sec-
tion 2. Kinase activity was measured in the presence of either 50 WM lysoplasmenylcholine, 50 WM lysophosphatidylinositol, 50 WM lysoplas-
menylethanolamine, 50 WM lysophosphatidylserine, 50 WM palmitoyl carnitine, or 50 WM phosphatidic acid (panel A). Mono Q-puri¢ed PKA
from DE-52 fractionated rabbit heart cytosol was also assayed for kinase activity utilizing the Kemptide phosphorylation assay in the presence
of indicated concentrations of lysoplasmenylcholine (a), lysophosphatidylcholine (F), platelet activating factor (O), or lysoplatelet activating
factor (R) as described in Section 2 (panel B).
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pholipase C (diacylglycerol and the plasmalogenic diglyceride,
1-O-alk-1P-enyl-2-acyl-sn-glycerol), and phospholipase D
(phosphatidic acid) [13,14]. Other kinases recently shown to
be activated by phospholipids include phosphatidic acid-acti-
vated protein kinase and Raf-1 by phosphatidic acid [15,16].
The present results demonstrating the activation of PKA by
lysoplasmenylcholine represent another mechanism through
which accelerated phospholipolysis may be coupled to protein
kinases.
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